

# Vandana G Abramson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5676491/publications.pdf>

Version: 2024-02-01

42  
papers

2,891  
citations

304743

22  
h-index

265206

42  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4551  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sacituzumab Govitecan-hzjy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	27.0	542
2	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
3	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	1.6	283
4	Subtyping of triple-negative breast cancer: Implications for therapy. <i>Cancer</i> , 2015, 121, 8-16.	4.1	280
5	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clinical Cancer Research</i> , 2017, 23, 4035-4045.	7.0	104
6	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	3.7	94
7	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	9.4	92
8	Genomic profiling of ER <sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
9	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	7.0	91
10	Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. <i>Cancer Research</i> , 2015, 75, 4697-4707.	0.9	86
11	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	3.8	85
12	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1963.	7.4	81
13	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. <i>Journal of Clinical Oncology</i> , 2016, 34, 2303-2311.	1.6	80
14	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
15	New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available. <i>Clinical Cancer Research</i> , 2011, 17, 952-958.	7.0	65
16	Molecular Heterogeneity of Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 154-158.	1.0	58
17	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. <i>Cancer Research</i> , 2015, 75, 405-414.	0.9	53
18	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	7.0	37

#	ARTICLE	IF	CITATIONS
19	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	1.6	36
20	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3896-3904.	7.0	36
21	Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. <i>Clinical Breast Cancer</i> , 2015, 15, 171-180.	2.4	35
22	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	7.0	29
23	An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using <sup>18</sup> F-NaF. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1138-1143.	5.0	22
24	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
25	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5207.	4.1	20
26	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	7.0	19
27	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	2.5	18
28	Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2374-2380.	6.4	16
29	Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961772535.	0.6	16
30	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 45.	5.2	16
31	Longitudinal, intermodality registration of quantitative breast PET and MRI data acquired before and during neoadjuvant chemotherapy: Preliminary results. <i>Medical Physics</i> , 2014, 41, 052302.	3.0	15
32	A Phase Ib Dose Escalation Trial of RO4929097 (a $\beta$ -secretase inhibitor) in Combination with Exemestane in Patients with ER+ Metastatic Breast Cancer (MBC). <i>Clinical Breast Cancer</i> , 2022, 22, 103-114.	2.4	13
33	Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. <i>Clinical Breast Cancer</i> , 2020, 20, 344-352.e1.	2.4	11
34	Detection of breast cancer microcalcification using <sup>99m</sup> Tc-MDP SPECT or Osteosense 750EX FMT imaging. <i>Nuclear Medicine and Biology</i> , 2015, 42, 269-273.	0.6	9
35	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
36	Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 357-364.	2.5	5

#	ARTICLE	IF	CITATIONS
37	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	2.5	4
38	Combining multiparametric MRI with receptor information to optimize prediction of pathologic response to neoadjuvant therapy in breast cancer: preliminary results. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	1.5	4
39	Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB). <i>Cancer Research</i> , 2022, 82, PD4-04-PD4-04.	0.9	3
40	Clinical Utility of Serum Tumor Markers and Circulating Tumor Cell Assays in the Treatment of Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2011, 12, 403-411.	3.0	2
41	Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer. <i>Tomography</i> , 2020, 6, 170-176.	1.8	2
42	53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). <i>Neuro-Oncology Advances</i> , 2020, 2, ii11-ii11.	0.7	1